These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

755 related items for PubMed ID: 31326345

  • 1. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, Kassam Z, Sadovsky RG, Elliott RJ, Budree S, Kim M, Keller MJ.
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
    [Abstract] [Full Text] [Related]

  • 2. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
    Johnsen PH, Hilpüsch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, Goll R.
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):17-24. PubMed ID: 29100842
    [Abstract] [Full Text] [Related]

  • 3. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.
    Halkjær SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH, Petersen AM.
    Gut; 2018 Dec; 67(12):2107-2115. PubMed ID: 29980607
    [Abstract] [Full Text] [Related]

  • 4. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T, Joossens M, Vázquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, Verhasselt B, van Vlierberghe H, De Vos M, Raes J, De Looze D.
    Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study.
    El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T.
    Gut; 2020 May; 69(5):859-867. PubMed ID: 31852769
    [Abstract] [Full Text] [Related]

  • 6. The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: results from a randomised, double-blind, placebo-controlled study.
    Madsen AMA, Halkjær SI, Christensen AH, Günther S, Browne PD, Kallemose T, Hansen LH, Petersen AM.
    Scand J Gastroenterol; 2021 Jul; 56(7):761-769. PubMed ID: 34000958
    [Abstract] [Full Text] [Related]

  • 7. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
    Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillilä M, Punkkinen J, Koskenpato J, Anttila VJ, Tillonen J, Satokari R, Arkkila P.
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1321-1331. PubMed ID: 32343000
    [Abstract] [Full Text] [Related]

  • 8. Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea.
    Yau YK, Su Q, Xu Z, Tang W, Ching JYL, Mak JWY, Cheung CP, Fung M, Ip M, Chan PKS, Wu JCY, Chan FKL, Ng SC.
    Aliment Pharmacol Ther; 2023 Oct; 58(8):795-804. PubMed ID: 37667968
    [Abstract] [Full Text] [Related]

  • 9. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
    Andresen V, Gschossmann J, Layer P.
    Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):658-666. PubMed ID: 32277872
    [Abstract] [Full Text] [Related]

  • 10. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults.
    Kemppinen A, Howell C, Allgar V, Dodd M, Gregson J, Knowles C, McLaughlin J, Pandya P, Whorwell P, Markaryan E, Yiannakou Y.
    Trials; 2020 Jan 30; 21(1):122. PubMed ID: 32000822
    [Abstract] [Full Text] [Related]

  • 11. Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome.
    El-Salhy M, Casen C, Valeur J, Hausken T, Hatlebakk JG.
    World J Gastroenterol; 2021 May 14; 27(18):2219-2237. PubMed ID: 34025075
    [Abstract] [Full Text] [Related]

  • 12. The effect of fecal microbiota transplantation on IBS related quality of life and fatigue in moderate to severe non-constipated irritable bowel: Secondary endpoints of a double blind, randomized, placebo-controlled trial.
    Johnsen PH, Hilpüsch F, Valle PC, Goll R.
    EBioMedicine; 2020 Jan 14; 51():102562. PubMed ID: 31877418
    [Abstract] [Full Text] [Related]

  • 13. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome.
    Srivastava S, Basak U, Naghibi M, Vijayakumar V, Parihar R, Patel J, Jadon PS, Pandit A, Dargad RR, Khanna S, Kumar S, Day R.
    Gut Microbes; 2024 Jan 14; 16(1):2338322. PubMed ID: 38630015
    [Abstract] [Full Text] [Related]

  • 14. Engraftment of strictly anaerobic oxygen-sensitive bacteria in irritable bowel syndrome patients following fecal microbiota transplantation does not improve symptoms.
    Browne PD, Cold F, Petersen AM, Halkjær SI, Christensen AH, Günther S, Hestbjerg Hansen L.
    Gut Microbes; 2021 Jan 14; 13(1):1-16. PubMed ID: 34074214
    [Abstract] [Full Text] [Related]

  • 15. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.
    Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP.
    BMC Gastroenterol; 2018 May 25; 18(1):71. PubMed ID: 29801486
    [Abstract] [Full Text] [Related]

  • 16. The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors.
    Lin H, Guo Q, Wen Z, Tan S, Chen J, Lin L, Chen P, He J, Wen J, Chen Y.
    Microb Cell Fact; 2021 Dec 28; 20(1):233. PubMed ID: 34963452
    [Abstract] [Full Text] [Related]

  • 17. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome.
    Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC.
    Aliment Pharmacol Ther; 2019 Aug 28; 50(3):240-248. PubMed ID: 31136009
    [Abstract] [Full Text] [Related]

  • 18. Protocol for faecal microbiota transplantation in irritable bowel syndrome: the MISCEAT study - a randomised, double-blind cross-over study using mixed microbiota from healthy donors.
    Hurych J, Vejmelka J, Hlinakova L, Kramna L, Larionov V, Kulich M, Cinek O, Kohout P.
    BMJ Open; 2022 Jun 27; 12(6):e056594. PubMed ID: 35760542
    [Abstract] [Full Text] [Related]

  • 19. Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis.
    Halkjær SI, Lo B, Cold F, Højer Christensen A, Holster S, König J, Brummer RJ, Aroniadis OC, Lahtinen P, Holvoet T, Gluud LL, Petersen AM.
    World J Gastroenterol; 2023 May 28; 29(20):3185-3202. PubMed ID: 37346153
    [Abstract] [Full Text] [Related]

  • 20. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Haifer C, Paramsothy S, Kaakoush NO, Saikal A, Ghaly S, Yang T, Luu LDW, Borody TJ, Leong RW.
    Lancet Gastroenterol Hepatol; 2022 Feb 28; 7(2):141-151. PubMed ID: 34863330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.